Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
Retrieved on:
Thursday, November 30, 2023
A total of ten patients are now being followed in the EA Program.
Key Points:
- A total of ten patients are now being followed in the EA Program.
- The Intermediate Size EA Program for na-SPMS represents a critical step forward in Tiziana Life Sciences' mission to provide treatment options for patients living with this debilitating disease while collecting valuable regulatory evidence about this novel investigational therapy.
- "We are pleased to announce the commencement of dosing in the second intermediate-sized patient cohort for our na-SPMS Expanded Access Program," said Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
- "Our dedication to advancing the field of multiple sclerosis research and providing patients with innovative treatment options is unwavering.